<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: SMAD4 is a <z:chebi fb="1" ids="15841">polypeptide</z:chebi> with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor function being investigated as a prognostic biomarker in Union Internationale Contre le <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> stages II and III in previous studies, but its role as a prognostic marker in <z:e sem="disease" ids="C0677950" disease_type="Neoplastic Process" abbrv="">stage IV colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) is still undefined </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated the prognostic value of reduced SMAD4 expression in patients with metastatic (mCRC) under first-line <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-containing combination chemotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS AND METHODS: <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> samples were obtained from patients who took part in a prospective randomized phase III chemotherapy trial of the Arbeitsgemeinschaft Internistische Onkologie of the German <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Society colorectal study group, comparing the use of <z:chebi fb="0" ids="31348">capecitabine</z:chebi> plus <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> with infusional <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> (5-FU) plus <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> as first-line therapy in mCRC </plain></SENT>
<SENT sid="3" pm="."><plain>SMAD4 expression was determined by immunohistochemistry </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> tissues from 230 patients were obtained </plain></SENT>
<SENT sid="5" pm="."><plain>Reduced SMAD4 expression was identified in 34% of samples </plain></SENT>
<SENT sid="6" pm="."><plain>Patients with reduced nuclear SMAD4 expression in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue showed a shorter progression-free survival (PFS; 7.0 months vs. 8.9 months; P = .024) and overall survival (OS; 13.9 months vs. 17.8 months; P = .044) compared with patients retaining SMAD4 expression </plain></SENT>
<SENT sid="7" pm="."><plain>The effect of SMAD4 expression on PFS and OS could be demonstrated in univariate and multivariate analyses </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Our data demonstrate the importance of reduced SMAD4 expression in patients with mCRC receiving chemotherapy with <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> and 5-FU </plain></SENT>
</text></document>